FDA-RFQ- BioProfile FLEX2 Parts and Components-Brand Name or Equal CDER-2026-133117
Summary
AI-generated · Jun 17, 2026Provide brand-name or equal BioProfile FLEX 2 parts and consumables compatible with three FDA-owned Nova BioProfile FLEX 2 instruments, including an external sampling module attached to one unit. A single contractor shall supply all items listed in the SOW, ensuring full compatibility with the configured instruments without modifying them. Items must be new and unused (no grey market or refurbished products); items requiring refrigeration or classified as flammable must be shipped under cold-chain conditions per manufacturer specifications and applicable transport regulations, with 75–80% of shelf life remaining at delivery.
The contractor must be the original manufacturer or an authorized reseller. The procurement covers a 12-month period starting on award. Requirements include identifying instrument identity (manufacturer, instrument name/model, and all instrument serial numbers), ensuring compatibility and proper function as an automated bioanalysis system for cell culture monitoring (measuring pH, dissolved gases, metabolites, osmolality, and cell density), and delivering new, defect-free items. Place of performance is the FDA facility in Silver Spring, Maryland. Quotes are to be submitted by email to the designated FDA contact.
Request for Quotation: FDA-RFQ-CDER-2026-133117 BioProfile FLEX2 Parts and Components-Brand Name or Equal Notice of Combined Synopsis/Solicitation This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with part 12. This announcement constitutes the only solicitation; quotes are being requested, and a separate written solicitation will not be issued. Background The Center for Drug Evaluation and Research (CDER) requires operational parts and consumables for three (3) currently owned Nova BioProfile Flex 2 instruments. To meet the purpose and objective of this requirement, a single Contractor shall provide the parts and components listed in the Statement of Work (SOW) that must be compatible with the corresponding three (3) NOVA BioProfile Flex 2 instruments: Main FLEX2 instrument 1: Serial Number- T262230070C Main FLEX2 instrument 2: Serial Number- T26817050C External sampling module for instrument 2: T2761720PC Main FLEX2 instrument 3: Serial Number- T26A200050C Please note Main FLEX2 instrument 2 has two serial numbers because it has an additional module added which has its own Serial Number. The offeror is also expected to adhere to the: the established delivery times as expressed in Section 5.1 of the attached combined solicitation/synopsis the fullest extent practicable. Minimum Salient Characteristic Requirements: 1. Compatibility is needed for three currently owned Nova BioProfile Flex 2 instruments as described in this Section (Section 5). The Contractor shall identify the following salient characteristics for BioProfile Flex-2 commercial parts and consumables or equal 2. Instrument identity: Manufacturer (Nova Biomedical), instrument name and model (BioProfile FLEX 2), and all three serial numbers of the government-owned instruments 3. Instrument function: Automated bioanalysis system for cell culture monitoring, measuring parameters such as pH, dissolved gases, metabolites, osmolality, and cell density 4. Compatibility requirement: All parts and consumables supplied must be fully compatible with and functional in the Nova BioProfile FLEX 2 as configured at the FDA facility, without modification to the instrument 5. Quality standard: All items must be new, unused, and free from defects; grey market and refurbished products are unacceptable 6. Shelf life: All items must arrive with at least 75% to 80% of their total shelf life remaining upon delivery 7. Cold chain: Items requiring refrigeration or classified as flammable must be shipped and delivered in accordance with manufacturer specifications and applicable DOT/IATA regulations 8. Authorization: Offeror must be the manufacturer or an authorized reseller of the items quoted Place of Performance: Food and Drug Administration Attn: Erica Berilla 10903 New Hampshire Ave Bldg. 52/72 RM 2232 Silver Spring, MD 20903 Period of Performance: 12 consecutive months commencing upon date of Award. Please see the attached Statement of Work and Corresponding Justification for reference/utilization. Quotes are due by email on or before June 26, 2025, by 12:00 P.M. (Eastern Daylight Time) and should be sent to brandon.rafus@fda.hhs.gov.
From Combined Synopsis/Solicitation posted on Jun 16, 2026Notice history
1Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA